ω-3 fatty acids prevent hepatic steatosis, independent of PPAR-α activity, in a murine model of parenteral nutrition-associated liver disease

Journal of Parenteral and Enteral Nutrition

Volumn 38, Issue 5, 2014, Pages 608-616

  Prince, Esther ^a   Lazare, Farrah B ^a,b   Treem, William R ^a,c   Xu, Jiliu ^a   Iqbal, Jahangir ^d   Pan, Xiaoyue ^d   Josekutty, Joby ^d   Walsh, Meghan ^d   Anderson, Virginia ^a   Hussain, M Mahmood ^d   Schwarz, Steven M ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b WINTHROP UNIVERSITY   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

microsomal triglyceride transfer protein; parenteral nutrition associated liver disease; peroxisome proliferator activated receptor ; steatosis; 3 fatty acids

Indexed keywords

CHOLESTEROL; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; SODIUM CHLORIDE; TRIACYLGLYCEROL; CARRIER PROTEIN;

129S1/SVIMJ MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; FATTY LIVER; FEEDING; KNOCKOUT MOUSE; LIPID STORAGE; LIVER DISEASE; LIVER HISTOLOGY; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PARENTERAL NUTRITION; PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ANIMAL; DEFICIENCY; DIET THERAPY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INBRED MOUSE STRAIN; LIVER; METABOLISM; TREATMENT OUTCOME;

ANIMALS; CARRIER PROTEINS; CHOLESTEROL; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; FATTY LIVER; LIVER; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; PARENTERAL NUTRITION; PPAR ALPHA; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84904756056     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/0148607113491436     Document Type: Article

References (56)

1. Kelly DA. Liver complications of pediatric parenteral nutrition - epidemiology. Nutrition. 1998 ; 14: 153-157 (Pubitemid 28049003)
2. Levine A, Maayan A, Shamir R, et al. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab. 1999 ; 12: 549-553 (Pubitemid 29334735)
3. Kaufman SS. Prevention of parenteral nutrition-associated liver disease in children. Pediatr Transplant. 2002 ; 6: 37-42 (Pubitemid 34269734)
4. Wang H, Khaoustov VI, Krishnan B, et al. Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets. J Nutr. 2006 ; 136: 2547-2552 (Pubitemid 44521611)
5. Loff S, Waag KL, Kranzlin B, et al. Long-term total parenteral nutrition-induced hepatobiliary dysfunction in a rabbit model. J Pediatr Surg. 1998 ; 33: 694-699 (Pubitemid 28213208)
6. Katayama T, Tanaka M, Tanaka K, et al. Alterations in hepatic mitochondrial function during total parenteral nutrition in immature rats. JPEN J Parenter Enteral Nutr. 1990 ; 14: 640-645
7. Tazuke Y, Drongowski RA, Btaiche I, et al. Effects of lipid administration on liver apoptotic signals in a mouse model of total parenteral nutrition (TPN). Pediatr Surg Int. 2004 ; 20: 224-228 (Pubitemid 38899924)
8. Musso G, Gambino R, Cassader M, et al. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009 ; 48: 1-26
9. Castro J, Amigo L, Miquel JF, et al. Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology. 2007 ; 45: 1261-1266 (Pubitemid 46775789)
10. Letteron P, Sutton A, Mansouri A, et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003 ; 38: 133-140 (Pubitemid 36775804)
11. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. 2006 ; 130: 1661-1669 (Pubitemid 43668848)
12. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996 ; 24: 200-208 (Pubitemid 26059117)
13. Pan X, Hussain FN, Iqbal J, et al. Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. J Biol Chem. 2007 ; 282: 17078-17089 (Pubitemid 47093224)
14. Sugimoto T, Yamashita S, Ishigami M, et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol. 2002 ; 36: 157-162 (Pubitemid 34146421)
15. Ameen C, Edvardsson U, Ljungberg A, et al. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem. 2005 ; 280: 1224-1229
16. Ip E, Farrell G, Hall P, et al. Administration of the potent PPAR-alpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004 ; 39: 1286-1296 (Pubitemid 38569050)
17. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999 ; 31: 384 (Pubitemid 29349772)
18. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006 ; 22: 873-883 (Pubitemid 43875555)
19. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996 ; 23: 1464-546
20. Chen WJ, Yeh SL, Huang PC. Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. Clin Nutr. 1996 ; 15: 24-28 (Pubitemid 26065369)
21. Alwayn IP, Gura K, Nose V, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 ; 57: 445-452 (Pubitemid 40293615)
22. Van Aerde JE, Duerksen DR, Gramlich L, et al. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res. 1999 ; 45: 202-208 (Pubitemid 29075996)
23. Chen WJ, Yeh SL. Effects of fish oil in parenteral nutrition. Nutrition. 2003 ; 19: 275-279
24. Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006 ; 83: 1505S - 1519S (Pubitemid 44713092)
25. Neschen S, Moore I, Regittnig W, et al. Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. Am J Physiol Endocrinol Metab. 2002 ; 282: E395 - E401
26. Burdge GC, Finnegan YE, Minihane AM, et al. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C] alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. Br J Nutr. 2003 ; 90: 311-321 (Pubitemid 36992532)
27. Willumsen N, Hexeberg S, Skorve J, et al. Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. J Lipid Res. 1993 ; 34: 13-22 (Pubitemid 23016617)
28. Moran Penco JM, Macia BE, Salas MJ, et al. Liver lipid composition and intravenous, intraperitoneal, and enteral administration of intralipid. Nutrition. 1994 ; 10: 26-31
29. Kalfarentzos F, Spiliotis J, Christopoulos D, et al. Total parenteral nutrition by intraperitoneal feeding in rabbits. Eur Surg Res. 1988 ; 20: 352-357 (Pubitemid 19045251)
30. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 ; 41: 1313-1321 (Pubitemid 40770284)
31. Iqbal J, Hussain MM. Evidence for multiple complementary pathways for efficient cholesterol absorption in mice. J Lipid Res. 2005 ; 46: 1491-1501 (Pubitemid 43109814)
32. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 ; 37: 911-917
33. Athar H, Iqbal J, Jiang XC, Hussain MM. A simple, rapid, and sensitive fluorescence assay for microsomal triglyceride transfer protein. J Lipid Res. 2004 ; 45: 764-772 (Pubitemid 38405684)
34. Edwards IJ, O'Flaherty JT. Omega-3 fatty acids and PPARgamma in cancer. PPAR Res. 2008 ; 2008: 358052
35. Deckelbaum RJ, Worgall TS, Seo T. n-3 Fatty acids and gene expression. Am J Clin Nutr. 2006 ; 83: S1520 - S1525
36. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun. 2000 ; 278: 704-711
37. Orasanu G, Ziouzenkova O, Devchand PR. The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008 ; 52: 869-881
38. Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 ; 281: 8748-8755 (Pubitemid 43847980)
39. Chen WJ, Yeh SL, Huang PC. Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. Clin Nutr. 1996 ; 15: 24-28 (Pubitemid 26065369)
40. Ntambi JM, Miyazaki M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res. 2004 ; 43 (2). 91-104 (Pubitemid 37487985)
41. Sekiya M, Yahaqi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steratosis in obese mice by SREBP-1 suppression. Hepatology. 2003 ; 38: 1529-1539 (Pubitemid 37466979)
42. Javid PJ, Greene AK, Garza J, et al. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg. 2005 ; 40: 1446-1453 (Pubitemid 41248009)
43. Le HD, Fallon EM, Kalish BT, et al. The effect of varying ratios of docosahexaenoic acid and arachidonic acid in the prevention and reversal of biochemical essential fatty acid deficiency in a murine model. Metabolism. 2013 ; 62: 499-508
44. Alwayn IPJ, Javid PJ, Gura KM, et al. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency?. Hepatology. 2004 ; 39: 1176-1177
45. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004 ; 39: 608-616 (Pubitemid 38337640)
46. Ip E, Farrell GC, Robertson G, et al. Central role of PPAR alpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003 ; 38: 123-132 (Pubitemid 36775803)
47. Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999 ; 103: 1489-1498
48. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol. 2001 ; 35: 17-23 (Pubitemid 32646220)
49. Matsusue K, Kusakabe T, Noguchi T, et al. Hepatic steatosis in leptin-deficient mice is promoted by the PPARγ target gene, fat-specific protein 27. Cell Metab. 2008 ; 7: 302-311 (Pubitemid 351455219)
50. Larter CZ, Yeh MM, Cheng J, et al. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol. 2008 ; 23: 267-275 (Pubitemid 351257676)
51. Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002 ; 277: 34182-34190
52. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature. 2007 ; 445: 219-223 (Pubitemid 46095727)
53. Yoshikawa T, Ide T, Shimano H, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism, I: PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol. 2003 ; 17: 1240-1254 (Pubitemid 36819948)
54. Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition. 1998 ; 14: 158-164 (Pubitemid 28049004)
55. Su K, Nadezhda SS, Lu J. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independent of phytosterol accumulation. J Biol Chem. 2012 ; 287: 28564-28575
56. Skouroliakou M, Konstantinou D, Koutri K, et al. A double-blind, randomized clinical trial of the effect of omega-3 fatty acids on the oxidative stress of preterm neonates fed through parenteral nutrition. Eur J Clin Nutr. 2010 ; 64: 940-947